Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP (Q68971136)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

title

Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

author name string

Steward W

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

Jones M

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

Deakin D

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

Todd I

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

Wilkinson P

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

Scarffe JH

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

Harris M

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

Crowther D

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

publication date

1 April 1986

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

published in

Hematological Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

page(s)

135-147

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study

28 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Value of prednisone in combination chemotherapy of stage IV Hodgkin's disease. Report from the British National Lymphoma Investigation

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Curative potential of combined modality therapy for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Combination chemotherapy in advanced Hodgkin's disease. Induction and maintenance of remission

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Evaluation of the significance of prognostic factors in stage III Hodgkin's disease treated with MOPP and radiotherapy

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Prednisone in MOPP chemotherapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Treatment of Hodgkin's disease using intensive chemotherapy followed by irradiation

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Combination chemotherapy in generalized Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

A comparative study of a bcnu containing 4-drug program versus mopp versus 3-drug combinations in advanced Hodgkin's disease.A cooperative study by the cancer and leukemia group B

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Childhood Hodgkin's disease in Uganda: a ten year experience

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Combined modality therapy of Hodgkin's disease.A report on the stanford trials

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Alternating drug combinations in the treatment of advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

MVPP chemotherapy regimen for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience

1 reference

https://api.crossref.org/works/10.1002%2FHON.2900040206

7 January 2021

Identifiers

DOI

10.1002/HON.2900040206

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:2427429%20AND%20SRC:MED&resulttype=core&format=json

28 September 2019

1 reference